Hansa Biopharma Submits BLA to FDA
-
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
19 Dec 2025, 20:35
Regulatory informationPRESS RELEASE
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients
Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
FDA has granted Hansa Biopharma Fast Track and Orphan Drug Designation and Hansa has requested Priority Review
.. Renée Aguiar-Lucander, CEO, Hansa Biopharma said: “The submission of our BLA to the FDA marks a pivotal milestone for Hansa Biopharma and for highly sensitized patients living with end-stage renal disease in the US. If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant that would otherwise be out of reach. ..”
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind